Cyteir Therapeutics, Inc. is developing the next generation of synthetic lethal therapies to treat cancer and autoimmune disease. Cyteir is a leader in the discovery and development of novel therapeutics based on the biology of DNA repair and synthetic lethality for the treatment of cancer and autoimmune diseases. Our initial approach takes advantage of DNA damage overload to induce selective self-destruction of cells by targeting the DNA repair activity of RAD51.
Cyteir Therapeutics Announces First Patient Dosed in Phase 2 with CYT-0851
Feb 08, 2022
Posted by Cyteir Therapeutics